Your browser doesn't support javascript.
loading
Enfermedad cardiovascular en tiempos de COVID-19 / Cardiovascular disease in times of COVID-19
Lamelas, Pablo; Botto, Fernando; Pedernera, Gustavo; Alves De Lima, Alberto; Costabel, Juan Pablo; Belardi, Jorge.
  • Lamelas, Pablo; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
  • Botto, Fernando; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
  • Pedernera, Gustavo; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
  • Alves De Lima, Alberto; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
  • Costabel, Juan Pablo; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
  • Belardi, Jorge; Instituto Cardiovascular de Buenos Aires. Buenos Aires. AR
Medicina (B.Aires) ; 80(3): 248-252, jun. 2020. graf
Article in Spanish | LILACS | ID: biblio-1125076
RESUMEN
Existen crecientes informes sobre una drástica caída en consultas y realización de procedimientos cardiovasculares (incluyendo urgencias y emergencias) en regiones afectadas por la pandemia de COVID-19, con el consecuente incremento marcado de la mortalidad total que no se explica totalmente por las defunciones atribuidas a COVID-19. En Argentina, la enfermedad cardiovascular lidera el ranking de muertes en adultos con 280 muertes por día, y en las últimas décadas hemos reducido su mortalidad entre 20 y 30% mediante diversas intervenciones basadas en la evidencia. En el presente trabajo realizamos análisis predictivos para entender cuáles podrían ser las consecuencias de una peor implementación de dichas intervenciones. Estimamos que un menor control de los factores de riesgo cardiovascular de abril a octubre de 2020 podría causar hasta 10 500 nuevos casos prevenibles de enfermedad cardiovascular. En términos de infarto de miocardio, una caída del 40% al 60% del tratamiento de reperfusión podría incrementar la mortalidad del 3% al 5%. Un incremento marginal de riesgo relativo de 10% a 15% de muerte cardiovascular equivaldría a un exceso de 6000 a 9000 muertes evitables. En conclusión, dada la alta prevalencia y fatalidad de la enfermedad cardiovascular, incluso un pequeño impacto negativo en la eficacia de su cuidado se traducirá en grandes cantidades de afectados en Argentina. Es necesario informar a las autoridades y educar al público para que sigan controlando enfermedades cardiovasculares y sus factores de riesgo, siempre que existan recursos y minimizando el riesgo de contagio y propagación del virus.
ABSTRACT
There are increasing reports of a drastic drop in consultations and cardiovascular procedures (including urgencies and emergencies) in regions affected by the COVID-19 pandemic, with a consequent marked increase in total mortality that is not fully explained by COVID-19. Cardiovascular disease leads the ranking in deaths in adults in Argentina with 280 deaths per day, and in recent decades we have reduced its mortality by 20-30% through various evidence-based interventions. Herein we conducted predictive analyses to understand what could be the consequences of a worse implementation of those interventions. We estimate that less control of cardiovascular risk factors from April to October 2020 could cause up to 10 500 new preventable cases of cardiovascular disease. In terms of myocardial infarction, a drop from 40% to 60% of the reperfusion treatment could increase mortality by 3% to 5%. A marginal 10% to 15% increase in relative risk of cardiovascular death would be equivalent to an excess of 6000 to 9000 preventable deaths. In conclusion, given the high prevalence and fatality of cardiovascular disease, even a small negative impact on the efficacy of its care will translate into large numbers of people affected in Argentina. It is necessary to inform the authorities and educate the public so cardiovascular diseases and their risk factors remain a health priority, as long as resources exist and minimizing the risk of contagion and spread of the virus.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Pneumonia, Viral / Cardiovascular Diseases / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Etiology study / Prevalence study / Prognostic study / Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Argentina Language: Spanish Journal: Medicina (B.Aires) Journal subject: Medicine Year: 2020 Type: Article Affiliation country: Argentina Institution/Affiliation country: Instituto Cardiovascular de Buenos Aires/AR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Pneumonia, Viral / Cardiovascular Diseases / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Etiology study / Prevalence study / Prognostic study / Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Argentina Language: Spanish Journal: Medicina (B.Aires) Journal subject: Medicine Year: 2020 Type: Article Affiliation country: Argentina Institution/Affiliation country: Instituto Cardiovascular de Buenos Aires/AR